Complete report is available @ http://www.reportsnreports.com/reports/239426-outsourced-ion-channel-testing-trends-2013.html . Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of thick, sticky mucus which clogs the lungs and leads to life-threatening lung infections; and obstructs pancreatic enzyme secretions that are essential for the body to break down and absorb nutrients. CF patients have a limited number of available treatment options and significant unmet needs still exist. Opportunities are significant for new therapies that will improve symptoms, change the course of this disease, as well as increase therapy options. The introduction of the first disease modifying therapy, Kalydeco (ivacaftor), by Vertex Pharmaceuticals, paved the way for a new class of therapies known as cystic fibrosis transmembrane conductance regulator (CFTR) modulators. During our forecast period, new CFTR modulators will enter the CF market and rapid growth is forecast.

1. OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity
Analysis and Forecasts to 2017
Single User PDF: US$ 5995
Corporate User PDF: US$ 17985
Order this report by calling
+1 888 391 5441 or Send an email
to sales@reportsandreports.com
with your contact details and
questions if any.
1© ReportsnReports.com / Contact sales@reportsandreports.com

2. OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity
Analysis and Forecasts to 2017
Summary
Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of
thick, sticky mucus which clogs the lungs and leads to life-threatening lung infections; and
obstructs pancreatic enzyme secretions that are essential for the body to break down and
absorb nutrients. CF patients have a limited number of available treatment options and
significant unmet needs still exist. Opportunities are significant for new therapies that will
improve symptoms, change the course of this disease, as well as increase therapy
options.
The introduction of the first disease modifying therapy, Kalydeco (ivacaftor), by Vertex
Pharmaceuticals, paved the way for a new class of therapies known as cystic fibrosis
transmembrane conductance regulator (CFTR) modulators. During our forecast period,
new CFTR modulators will enter the CF market and rapid growth is forecast.
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
2© ReportsnReports.com / Contact sales@reportsandreports.com

3. OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity
Analysis and Forecasts to 2017
Highlights
Key Questions Answered
-What are the pressing unmet needs and remaining opportunities in CF?
- What are the R&D strategies drugmakers are pursuing in the CF therapeutics space?
- Will CFTR modulators affect the management of CF?
- How promising are these agents; and how will they shape the CF market over the
coming five years?
- How will key product patent expiries in 2014 impact the CF therapeutics market?
- What unmet needs will new pipeline agents fulfil?
- What is the clinical and commercial positioning of pipeline products?
Inquiry for discount @
http://www.reportsnreports.com/contacts/discount.aspx?name=243173 .
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
3© ReportsnReports.com / Contact sales@reportsandreports.com

4. OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity
Analysis and Forecasts to 2017
Scope
- Overview of CF, including epidemiology, etiology, pathophysiology, symptoms and
current treatment options.
- Key topics covered include strategic product assessment, market characterization,
unmet needs, R&D strategies, clinical trial design and implications for the CF therapeutics
market.
- Pipeline analysis: comprehensive data split across different phases, emerging trends and
mechanisms of action under development, including inhaled antibiotics, CFTR modulators
and pancreatic enzyme products.
- Analysis of the current and future market competition in the US and five major EU CF
therapeutics market. Clinical and commercial benchmarking of promising pipeline
products versus standard of care treatments and competitive assessment of all therapies.
Insightful review of the key industry drivers, restraints and challenges.
Complete report is available @ http://www.reportsnreports.com/reports/239426-
outsourced-ion-channel-testing-trends-2013.html .
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
4© ReportsnReports.com / Contact sales@reportsandreports.com

5. OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity
Analysis and Forecasts to 2017
Key Benefits
- Identify the unmet needs and remaining opportunities in the CF therapeutics market.
- Develop business strategies by understanding the trends shaping and driving the US and
five major EU CF therapeutics market.
- Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Develop and design your in-licensing and out-licensing strategies through a review of
pipeline products and technologies.
- Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analyzing the performance of various emerging therapies.
Buy a copy of this report @
http://www.reportsnreports.com/purchase.aspx?name=243173 .
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
5© ReportsnReports.com / Contact sales@reportsandreports.com